Using human rights to strengthen TB research and access By Mike Frick Editor’s note: The following is based on the transcript of a plenary address delivered by the author at TB2016, a two-day TB conference held before the July International…
TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated
Letter from individuals and organizations, including TAG, expressing concern over selection of host cities to host World Conferences on Lung Health.
The End of TB Starts with Science: Eliminating tuberculosis (TB), the leading infectious killer in the world, won't happen without the critical leadership of the United States. Innovative policy making underpinned by catalyzing science has led to a dramatic reduction in the number of new TB cases each year in the country.
Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed.
Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
On December 4, 2015, in Cape Town, South Africa, Treatment Action Group, Harvard Medical School, Partners In Health, Treatment Action Campaign, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference in Barcelona. The symposium,…
Medical regulatory authorities fulfill an essential role by evaluating research and marketing applications for new products. They approve or reject applications based on data indicating safety, efficacy, and quality, gathered from scientifically controlled methods of data collection.
Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.